Finance

Lists
Why is HURA down ३.९६%?
Dive Deeper
HURA:NASDAQ
TuHURA Biosciences Inc
US$ १.३४
-३.९६%
(-०.०५५) 1D
नोभेम्बर १६, १४:४७:१० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HURA...
Open
US$ १.४२
High
US$ १.४३
Low
US$ १.२६
Mkt. cap
८.५१ करोड
Avg. vol.
४.१३ लाख
Volume
७.९७ लाख
52-wk high
US$ ३.४१
52-wk low
US$ ०.४१
EPS
-US$ ०.५४
Beta
-०.२३
Shares outstanding
६.३७ करोड
No. of employees
२२
Open
US$ १.४२
High
US$ १.४३
Low
US$ १.२६
Mkt. cap
८.५१ करोड
Avg. vol.
४.१३ लाख
Volume
७.९७ लाख
52-wk high
US$ ३.४१
52-wk low
US$ ०.४१
EPS
-US$ ०.५४
Beta
-०.२३
Shares outstanding
६.३७ करोड
No. of employees
२२
News stories
From web sources and news partners
Investor's Business Daily
Investor's Business Daily
·
३७ मिनेट पहिले
Tyson, Starbucks Lead The S&P 500, Nasdaq 100 As Investors Play Defense
Yahoo Finance
Yahoo Finance
·
२९ मिनेट पहिले
The S&P 500’s shot at 4 straight double-digit years is in Nvidia’s hands
The Korea Times
The Korea Times
·
१ घण्टा पहिले
Nasdaq, S&P 500 fall over 1% in run-up to Nvidia results, Anthropic debut
About TuHURA Biosciences Inc
CEO-
Employees२२
Founded१९९५
Headquartersताम्पा, फ्लोरिडा, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 2 analysts giving stock ratings to HURA in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for HURA in the last 3 months.
Highest
Current US$ १.३४
US$ १०.०० (+६४९.०६%)
Average
US$ ९.०० (+५७४.१६%)
Lowest
US$ ८.०० (+४९९.२५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason McCarthy
Maxim Group
Buy
Maintained
US$ ८.००
+४९९.३%
11/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ १०.००
+६४९.१%
10/27/2026
Silvan Turkcan
Citizens JMP
Buy
Initiated
US$ ९.००
+५७४.२%
04/27/2026
Unknown Analyst
Citizens JMP
Buy
Initiated
US$ ९.००
+५७४.२%
04/27/2026
Michael King
Rodman & Renshaw
Buy
Initiated
US$ ७.००
+४२४.३%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
६०.५५ लाख
५२.३३ लाख
६६.२० लाख
३७.०५ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२३.३८ लाख
२२.९७ लाख
२१.४३ लाख
१९.५६ लाख
Operating expense
८३.९४ लाख
७५.३० लाख
८७.६३ लाख
५६.६१ लाख
Total operating expenses
८३.९४ लाख
७५.३० लाख
८७.६३ लाख
५६.६१ लाख
Operating income
-८३.९४ लाख
-७५.३० लाख
-८७.६३ लाख
-५६.६१ लाख
Other non operating income
१.८५ लाख
-
-
-
EBT including unusual items
-६७.६१ लाख
-७५.३७ लाख
-९२.२३ लाख
-६४.१० लाख
EBT excluding unusual items
-८८.१७ लाख
-७५.३७ लाख
-९२.२३ लाख
-६४.१० लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-६७.६१ लाख
-७५.३७ लाख
-९२.२३ लाख
-६४.१० लाख
Net profit margin
-
-
-
-
Earnings per share
-०.१६
-०.१३
-
-०.१०
Interest and investment income
६०९.००
२१.२८ हजार
७.६२ हजार
३.६८ हजार
Interest expense
-६.०९ लाख
-२७.९७ हजार
-४.६८ लाख
-७.५३ लाख
Net interest expenses
-६.०८ लाख
-६.७० हजार
-४.६० लाख
-७.४९ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-८३.७१ लाख
-७५.०६ लाख
-८७.३५ लाख
-५६.३४ लाख
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू